Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Terazosin 5 mg after prior tamsulosin 0.2 mg in benign prostatic hyperplasia with lower urinary tract symptoms
KCT0004566Phase 4Not yet recruiting
- Sponsor
- Il-Yang Pharmaceutical
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of terazosin in benign prostatic hyperplasia (BPH), sponsored by Il-Yang Pharmaceutical. Planned start Dec 2019; status: not yet recruiting.
02
Drugs
terazosin
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on KCT0004566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004566.